Key result
Obesity with metabolic syndrome is linked to ~28% higher cystatin C levels versus healthy controls.
Why the study?
Serum cystatin C has been associated with cardiovascular disease, but its validity as a marker in obese patients without chronic kidney disease was unclear.
Are serum cystatin C levels elevated in obese patients with metabolic syndrome without chronic kidney disease compared to healthy controls?
Case-Control (n=68)
No
Are serum cystatin C levels elevated in obese patients with metabolic syndrome without chronic kidney disease compared to healthy controls?
Absolute Event Rate: 1.28% vs 1%
p-value: p=0.001
Serum cystatin C may be elevated in obese patients with metabolic syndrome prior to the development of overt chronic kidney disease, suggesting its potential utility as an early marker.
Serum cystatin C may flag early renal dysfunction in metabolic syndrome without overt CKD; this case-control association leaves open the need for prospective validation.
Background: Serum concentration of cystatin C, a marker of glomerular filtration has been associated with cardiovascular disease (CVD). The aim of this study was to evaluate cystatin C as a marker of obese patients without chronic kidney disease (CKD). Materials and Methods: The study population consisted of 36 subjects with metabolic syndrome and 32 subjects free of metabolic syndrome (the control group). HDL-C, LDL-C, blood urea, triglycerides, glucose, HbA1c, serum cystatin C and serum creatinine were measured in both groups. GFR was calculated in both groups using Cockroft-Gault equation. Results: Obese patients showed higher cystatin C levels than normal samples (, P
No takes yet. Share an insight, caveat, or question.
Asefy et al. (2012) conducted a case-control in Obesity Nephropathy / Metabolic Syndrome (n=68). Obesity with metabolic syndrome vs. Healthy controls without metabolic syndrome was evaluated on Serum cystatin C concentration (p=0.001). Obese patients with metabolic syndrome had significantly higher serum cystatin C levels compared to healthy controls (1.28 vs 1.00, p=0.001), indicating its potential as an early marker of renal dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: